Literature DB >> 30859342

Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.

Elisabet Pujadas1, Liam Chen1,2, Fausto J Rodriguez3,4.   

Abstract

Many breakthroughs have been made in the past decade regarding our knowledge of the biological basis of the diffuse gliomas, the most common primary central nervous system (CNS) tumors. These tumors as a group are aggressive, associated with high mortality, and have a predilection for adults. However, a subset of CNS glial and glioneuronal tumors are characterized by a more circumscribed pattern of growth and occur more commonly in children and young adults. They tend to be indolent, but our understanding of anaplastic changes in these tumors continues to improve as diagnostic classifications evolve in the era of molecular pathology and more integrated and easily accessible clinical databases. The presence of anaplasia in pleomorphic xanthoastrocytomas and gangliogliomas is assigned a WHO grade III under the current classification, while the significance of anaplasia in pilocytic astrocytomas remains controversial. Recent data highlight the association of the latter with aggressive clinical behavior, as well as the presence of molecular genetic features of both pilocytic and diffuse gliomas, with the recognition that the precise terminology remains to be defined. We review the current concepts and advances regarding histopathology and molecular understanding of pilocytic astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas, with a focus on their anaplastic counterparts.

Entities:  

Keywords:  Anaplasia; BRAF; Ganglioglioma; Pilocytic astrocytoma; Pleomorphic xanthoastrocytoma

Mesh:

Substances:

Year:  2019        PMID: 30859342      PMCID: PMC6494683          DOI: 10.1007/s10014-019-00336-z

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  59 in total

1.  Pleomorphic xanthoastrocytoma: what do we really know about it?

Authors:  C Giannini; B W Scheithauer; P C Burger; D J Brat; P C Wollan; B Lach; B P O'Neill
Journal:  Cancer       Date:  1999-05-01       Impact factor: 6.860

2.  Telomeric associations evolving to ring chromosomes in a recurrent pleomorphic xanthoastrocytoma.

Authors:  J R Sawyer; E L Thomas; G J Roloson; W M Chadduck; F A Boop
Journal:  Cancer Genet Cytogenet       Date:  1992-06

3.  Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas.

Authors:  Kerstin Kaulich; Britta Blaschke; Astrid Nümann; Andreas von Deimling; Otmar D Wiestler; Ruthild G Weber; Guido Reifenberger
Journal:  J Neuropathol Exp Neurol       Date:  2002-12       Impact factor: 3.685

4.  Comprehensive allelotype and genetic anaysis of 466 human nervous system tumors.

Authors:  A von Deimling; R Fimmers; M C Schmidt; B Bender; F Fassbender; J Nagel; R Jahnke; P Kaskel; E M Duerr; J Koopmann; D Maintz; S Steinbeck; W Wick; M Platten; D J Müller; R Przkora; A Waha; B Blümcke; R Wellenreuther; B Meyer-Puttlitz; O Schmidt; J Mollenhauer; A Poustka; A P Stangl; D Lenartz; K von Ammon
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

5.  Immunophenotype of pleomorphic xanthoastrocytoma.

Authors:  Caterina Giannini; Bernd W Scheithauer; Maria B S Lopes; Takanori Hirose; Johan M Kros; Scott R VandenBerg
Journal:  Am J Surg Pathol       Date:  2002-04       Impact factor: 6.394

6.  The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies.

Authors:  I Blümcke; K Giencke; E Wardelmann; S Beyenburg; T Kral; N Sarioglu; T Pietsch; H K Wolf; J Schramm; C E Elger; O D Wiestler
Journal:  Acta Neuropathol       Date:  1999-05       Impact factor: 17.088

7.  Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma.

Authors:  C Giannini; D Hebrink; B W Scheithauer; A P Dei Tos; C D James
Journal:  Neurogenetics       Date:  2001-07       Impact factor: 2.660

8.  Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.

Authors:  R G Weber; A Hoischen; M Ehrler; P Zipper; K Kaulich; B Blaschke; A J Becker; S Weber-Mangal; A Jauch; B Radlwimmer; J Schramm; O D Wiestler; P Lichter; G Reifenberger
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

9.  Malignant transformation of a dysembryoplastic neuroepithelial tumor after radiation and chemotherapy.

Authors:  Elisabeth J Rushing; Lester D Thompson; Hernando Mena
Journal:  Ann Diagn Pathol       Date:  2003-08       Impact factor: 2.090

10.  Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Otmar D Wiestler; Johannes Schramm
Journal:  Cancer       Date:  2004-07-01       Impact factor: 6.860

View more
  3 in total

1.  High-order radiomics features based on T2 FLAIR MRI predict multiple glioma immunohistochemical features: A more precise and personalized gliomas management.

Authors:  Jing Li; Siyun Liu; Ying Qin; Yan Zhang; Ning Wang; Huaijun Liu
Journal:  PLoS One       Date:  2020-01-22       Impact factor: 3.240

2.  Giant cell glioblastoma is a distinctive subtype of glioma characterized by vulnerability to DNA damage.

Authors:  Kaoru Ogawa; Akira Kurose; Akihisa Kamataki; Kenichiro Asano; Kosuke Katayama; Hidekachi Kurotaki
Journal:  Brain Tumor Pathol       Date:  2019-10-26       Impact factor: 3.298

3.  Discovering lethal alleles across the turkey genome using a transmission ratio distortion approach.

Authors:  E A Abdalla; S Id-Lahoucine; A Cánovas; J Casellas; F S Schenkel; B J Wood; C F Baes
Journal:  Anim Genet       Date:  2020-10-01       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.